Kenneth Attie
CIK 1454829 · SVP, CMO · last filed 2022-02-01
Kenneth Attie is a SVP, CMO who has filed 3 SEC Form 4 insider transactions across 2 companies since 2009. The most recent filing, for IMRA, was dated Feb 1, 2022. Current disclosed insider exposure totals $580.4K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$580.4K
2
3
$0
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IMRA | SVP, CMO | 34,100 | $17.02 | $580.4K | $0 | 2 | 2022-02-01 |
| Altus Pharmaceuticals Inc. (ALTU) Delisted | VP, Clinical Dev & Med Affairs | — | $10.12 | — | $0 | 1 | 2009-01-29 |
Recent Filings
3 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-02-01 | IMRA | Grant (A) | +34,100 | $0 | EDGAR |
| 2021-01-28 | IMRA | Grant (A) | — | $0 | EDGAR |
| 2009-01-29 | Altus Pharmaceuticals Inc. (ALTU) Delisted | Grant (A) | — | $0 | EDGAR |